Teriparatide

Teriparatide acts primarily as an agonist of the parathyroid hormone 1 receptor (PTH1R), a G-protein coupled receptor highly expressed on osteoblasts and osteocytes. Its anabolic effect is critically dependent on intermittent, once-daily administration, which induces a distinct signaling pattern compared to continuous PTH exposure.

PTH1R Activation and cAMP/PKA Pathway: Binding to PTH1R activates Gαs, stimulating adenylate cyclase and increasing intracellular cyclic AMP (cAMP). This activates protein kinase A (PKA), which phosphorylates transcription factors like CREB, leading to the expression of genes crucial for osteoblast differentiation, function, and survival, such as Runx2 and IGF-1.

Wnt/β-catenin Signaling Modulation: Intermittent PTH(1-34) indirectly enhances Wnt signaling, a key anabolic pathway for bone formation. It does this by transiently suppressing the expression of sclerostin (an inhibitor of Wnt signaling) from osteocytes and by downregulating Dickkopf-1 (Dkk1). This disinhibition allows Wnt ligands to stabilize β-catenin, promoting osteoblastogenesis.

RANKL/OPG Axis Regulation: Teriparatide has a complex, time-dependent effect on bone resorption. It initially increases the expression of RANKL on osteoblastic cells, which can stimulate osteoclast formation and activity. However, with continued intermittent dosing, it also increases the expression of its decoy receptor, osteoprotegerin (OPG), which helps to balance and eventually limit excessive resorption, allowing the anabolic formation to outpace resorption.

Osteoblast Lifecycle Effects: The peptide promotes the differentiation of pre-osteoblasts, inhibits apoptosis of mature osteoblasts and osteocytes, and can reactivate bone-lining cells, thereby increasing the number and lifespan of bone-forming cells.

Osteoporosis and Bone Fracture Healing: Teriparatide is extensively researched for its potent anabolic effects on bone. Studies demonstrate it significantly increases bone mineral density (BMD), improves bone microarchitecture (trabecular connectivity, cortical thickness), and reduces the risk of vertebral and non-vertebral fractures in postmenopausal and male osteoporosis. Research also explores its efficacy in accelerating fracture healing, particularly in non-unions or difficult-to-heal fractures, by stimulating callus formation and mineralization.

Osteonecrosis and Bone Defects: Investigations focus on its potential in treating osteonecrosis of the jaw (ONJ) and other avascular necrosis, where it may promote revascularization and new bone formation. Preclinical and clinical studies also examine its use in augmenting bone graft incorporation and healing of critical-sized skeletal defects.

Glucocorticoid-Induced Osteoporosis (GIOP): As a first-line anabolic therapy for GIOP, research confirms teriparatide is more effective than bisphosphonates at increasing BMD in patients on long-term glucocorticoids, addressing the profound suppression of bone formation caused by these drugs.

Dental and Periodontal Research: Studies investigate local or systemic administration of teriparatide to promote alveolar bone regeneration in periodontal disease, around dental implants (peri-implantitis), and for socket preservation following tooth extraction.

In clinical trials, common reported side effects include transient hypercalcemia, orthostatic hypotension, leg cramps, nausea, and dizziness. Injection site reactions (erythema, pain) may occur. A black box warning exists for an observed increase in osteosarcoma in Fischer 344 rats given lifetime, high-dose exposure; this risk has not been observed in humans but remains a theoretical concern, contraindicating use in patients at increased baseline risk for osteosarcoma. Anecdotal reports from research settings sometimes mention headache and fatigue. Theoretical concerns include exacerbation of pre-existing hypercalcemia or Paget's disease of bone.

For research purposes only. Not for human consumption. In established clinical research for osteoporosis, the standard and only FDA-approved dose is 20 mcg administered once daily via subcutaneous injection. Preclinical animal studies utilize a wide range of doses, often scaled by body weight (e.g., 5-40 mcg/kg in rodents), with varying frequencies (daily to intermittent) and routes (subcutaneous, local). Research protocols typically involve daily administration for durations ranging from 6 months to 2 years in human trials, with animal studies spanning weeks to months.

Neer, R.M., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine, 2001. 344(19): p. 1434-1441.
Dempster, D.W., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. Journal of Bone and Mineral Research, 2001. 16(10): p. 1846-1853.
Saag, K.G., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. New England Journal of Medicine, 2007. 357(20): p. 2028-2039.
Aspenberg, P., et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. Journal of Bone and Mineral Research, 2010. 25(2): p. 404-414.
Silva, B.C., and Bilezikian, J.P. Parathyroid hormone: anabolic and catabolic actions on the skeleton. Current Opinion in Pharmacology, 2015. 22: p. 41-50.
Keller, J., et al. Parathyroid hormone induces bone formation in phosphorylation-deficient PTHR1 knock-in mice. Journal of Bone and Mineral Research, 2018. 33(7): p. 1302-1312.
Tsai, J.N., et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. The Lancet, 2013. 382(9886): p. 50-56.